Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | DTYMK | P23919 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510894 | 1.00 | FUT5 (0.61) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL22381773 | 1.00 | FUT5 (0.61) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18521985 | 1.00 | FUT5 (0.61) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL22326689 | 0.95 | FUT5 (0.66) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18520989 | 0.93 | FUT5 (0.53) | FUT5TGM2RNASELP2RY2NT5E | |
| SCHEMBL18520837 | 0.93 | FUT5 (0.59) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18521628 | 0.93 | FUT5 (0.58) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18520836 | 0.93 | FUT5 (0.58) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18521309 | 0.93 | FUT5 (0.58) | FUT5TGM2RNASELP2RY1P2RY2 | |
| SCHEMBL18521330 | 0.93 | FUT5 (0.58) | FUT5TGM2RNASELP2RY1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | FUT5 4404/4885TGM2 3107/4885RNASEL 574/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | FUT5 4416/4885TGM2 2630/4885RNASEL 3097/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | FUT5 4404/4885TGM2 3107/4885RNASEL 574/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | FUT5 4404/4885TGM2 3107/4885RNASEL 574/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | FUT5 4192/4885TGM2 4222/4885RNASEL 1846/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | FUT5 4547/4885TGM2 2224/4885RNASEL 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.